LY-344,545

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
LY-344,545
LY-344,545 structure.png
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC20H19NO5
Molar mass353.37 g/mol g·mol−1
3D model (JSmol)
  (verify)

LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR2/3-selective LY-341,495.[1][2]

References[edit]

  1. ^ Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, et al. (January 1998). "2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability". Journal of Medicinal Chemistry. 41 (3): 358–78. doi:10.1021/jm970498o. PMID 9464367.
  2. ^ Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, et al. (September 2000). "A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices". British Journal of Pharmacology. 131 (2): 239–44. doi:10.1038/sj.bjp.0703574. PMC 1572327. PMID 10991916.